DOI: 10.36347/sasjm.2023.v09i09.009

Pages: 954-960

Schizophrenia can be effectively treated with the various antipsychotics on the market, but relapses, especially following poor compliance, can always recur and cause multiple complications. For this reason, long-acting antipsychotics have been developed. In Morocco, we only have paliperidone palmitate in its two monthly and quarterly forms. Objective: To describe the experience of Arrazi Hospital in Salé in the introduction of long-acting antipsychotics. Materials and methods: A retrospective descriptive and analytical study of 45 patients hospitalized and followed at Arrazi hospital in Salé, over a period between June 2020 and May 2023. The PANSS scale and the CGI clinical global impression scale were used. Results: The median age was 31 years, 88.9% were male, 86.7% had no occupation, 84.4% of participants had schizophrenia. 35.6% of patients had been hospitalized for between 5 and 10 years, and 35.6% for between 10 and 20 years. 84.4% of patients smoked, 80% used cannabis, and 15.56% had attempted suicide. The mean duration of treatment with paliperidone was 9.51 months ± 7.65. There was a statistically significant difference (p<0.001) between PANSS scores at admission, at D30 and at last observation, and also a statistically significant difference between PANSS scores at admission, at D30 and at last observation. Conclusion: Today, several formulations of long-acting antipsychotics are available, of which only paliperidone palmitate is available in Morocco. These treatments have proven their effectiveness in ensuring good therapeutic compliance.